

A systematic review and meta-analysis comparing the bias and accuracy of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations in community based populations.

Running head: Bias and accuracy of MDRD and CKD-EPI

Emily C. McFadden¹, Jennifer A. Hirst¹, Jan Y. Verbakel¹, Julie H. McLellan¹, F.D. Richard Hobbs^{1, 3}, Richard J. Stevens¹, Chris A. O'Callaghan^{2, 3}, Daniel S. Lasserson^{2,3,4*}

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

² Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

³ NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom

⁴ Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham

***Correspondence to: Professor Daniel Lasserson**

Address: Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT

Email: D.S.Lasserson@bham.ac.uk

Telephone: 0121 414 9093

Key words: Chronic Kidney Disease, glomerular filtration rate, MDRD, CKD-EPI

Word count: 2996

Analyses from this literature review have previously been presented at South West Society for Academic Primary Care (SW SAPC) 6/7 March 2014, Bristol.

Abbreviations: Glomerular filtration rate (GFR), estimated glomerular filtration rate (eGFR), measured glomerular filtration rate (mGFR), Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), confidence interval (CI), isotope dilution mass spectrometry (IDMS), Chronic kidney disease (CKD), quality assessment of diagnostic studies (QUADAS-2),

Abstract

Background: The majority of patients with chronic kidney disease are diagnosed and monitored in primary care. Glomerular filtration rate (GFR) is a key marker of renal function, but direct measurement is invasive; in routine practice, equations are used for estimated GFR (eGFR) from serum creatinine. We systematically assessed bias and accuracy of commonly used eGFR equations in populations relevant to primary care.

Content: MEDLINE, EMBASE and the Cochrane Library were searched for studies comparing measured GFR (mGFR) with eGFR in adult populations comparable to primary care and reporting both the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations based on standardised creatinine measurements. We pooled data on mean bias (difference between eGFR and mGFR) and on mean accuracy (proportion of eGFR within 30% of mGFR) using a random-effects inverse-variance weighted meta-analysis. We included 48 studies of 26,875 patients that reported data on bias and/or accuracy. Meta-analysis of within-study comparisons where both formulae were tested on the same patient cohorts using isotope dilution-mass spectrometry-traceable creatinine showed a lower mean bias in eGFR using CKD-EPI of 2.2 ml/min/1.73m² (95% CI 1.1 to 3.2; 30 studies; I²=74.4%) and a higher mean accuracy of CKD-EPI of 2.7% (1.6 to 3.8; 47 studies; I²=55.5%). Meta-regression showed that in both equations bias and accuracy favoured the CKD-EPI equation at higher mGFR values.

Summary: Both equations underestimated mGFR but CKD-EPI gave more accurate estimates of GFR.

1 INTRODUCTION

2 Chronic kidney disease (CKD) is associated with increased cardiovascular risk,
3 progression to end stage renal failure and reduced survival ([1](#), [2](#)), and is increasing
4 in prevalence globally ([3](#)). The majority of patients with CKD are managed in primary
5 care in the UK ([4](#)), and, in the absence of interventions that can specifically reverse a
6 decline in glomerular filtration rate (GFR) ([5](#)), management strategies address
7 common risk factors for cardio-renal outcomes, such as hypertension and diabetes.
8 Accurate identification of patients with CKD in primary care is therefore a key
9 underpinning public health strategy to reduce the burden of disease associated with
10 CKD.

11 While no easy method for directly measuring GFR exists, various indirect formulae,
12 including the Modification of Diet in Renal Disease (MDRD) Study equation ([6](#)) and
13 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation ([7](#)),
14 provide estimated GFR (eGFR) based upon serum creatinine and other factors that
15 influence creatinine production. These equations fulfil criteria important to a primary
16 care setting: they both use a routinely available blood biomarker that can be sampled
17 in primary care and require minimal additional patient level parameters. While
18 alternative renal biomarkers such as cystatin C can be incorporated into eGFR
19 equations ([8](#)) demonstrating improved correlation between eGFR and cardiovascular
20 risk ([9](#)), the lack of availability of cystatin C in routine primary care limits the use of
21 these equations in patients managed in the community.

22 The performance of creatinine-based eGFR equations in populations relevant to
23 primary care appears to vary. MDRD has been commonly used since 2000, but is
24 known to underestimate GFR, particularly in the early stages of CKD ([10](#)), which are
25 typically seen in primary care populations ([11](#)), and crucially around the cut point

between stages 2 and 3a, which in the UK determines entry onto a CKD primary care register and recommendations for routine annual monitoring ([12](#)). By comparison, CKD-EPI has shown improved agreement between measured and estimated GFR, especially in the earlier stages of CKD ([13](#)), although this was validated in a pooled dataset comprising research study participants and specific clinical populations rather than patients representative of those seen in primary care. Nevertheless, national guidance on monitoring renal function in the UK ([4](#)) and the USA ([5](#)) has been updated to recommend estimating GFR using CKD-EPI instead of MDRD.

There has been no reported systematic review and meta-analysis of studies that assess equation performance in populations specifically relevant to primary care, i.e., those with a lower prevalence of renal disease (and therefore higher mean eGFR) than the sets of individuals used for derivation and validation of routinely used formulae ([11](#)). We therefore systematically reviewed published studies comparing measured GFR (mGFR) with eGFR, calculated from both MDRD and CKD-EPI equations in populations relevant to a primary care setting.

MATERIAL AND METHODS

Data sources, searches and study selection

MEDLINE, EMBASE and the Cochrane Library were searched from inception until 23rd June 2017 for studies comparing mGFR using a reference method (radionuclide or iodinated tracers) with a simultaneous eGFR using the four variable MDRD formula and the CKD-EPI formula calculated from a creatinine assay standardized to isotope dilution-mass spectrometry methods. We included studies that recruited patients over 18 y of age in different healthcare settings; those not

recruiting primary care patients were assessed for similar mean age and renal function distributions to primary care populations ([11](#)). Studies recruiting highly selected patient populations not generalisable to primary care were excluded (transplanted organs, critical illness, single disorder case series) but not those prevalent in primary care, such as hypertension or diabetes. Studies were required to report either mean bias (mean difference between calculated eGFR and measured GFR) or accuracy (percentage of eGFR values within 30% of mGFR (P_{30}) ([4](#))). The search strategy is detailed in the online Supplemental Data file. A protocol for the systematic review was drafted for internal reference.

Data extraction and quality assessment

Two reviewers (JH, DL, JM, JV) independently selected abstracts for full text review and final inclusion, with any differences resolved by a third reviewer (CO'C, DL, EM). Two reviewers (JH, DL, JM, JV) extracted data in duplicate using a standardised data extraction form, with disagreement resolved by discussion and the third reviewer. Extracted items were mean bias, standard deviation (SD) or other measure of precision, accuracy, number of participants, recruitment setting, mean age, gender, co-morbid conditions and mean mGFR. Data on blood pressure, lipid concentrations, smoking status, body mass index and proteinuria were not extracted. Risk of bias was assessed using the revised tool for quality assessment of diagnostic studies (QUADAS-2) to assess bias and applicability of four domains: patient selection, index test, reference test, flow and timing ([14](#)).

Data synthesis and analysis

We present analyses of within-study comparisons of *i*) difference in bias between MDRD and CKD-EPI, in studies that compared both equations with mGFR and *ii*)

difference in accuracy between MDRD and CKD-EPI, both stratified into subgroups of high and low mGFR. We also report meta-analyses of bias and accuracy separately for the MDRD equation and the CKD-EPI equation compared to mGFR. Difference in bias was calculated by taking the differences in mean absolute bias between eGFR using CKD-EPI and MDRD equations. A negative difference in bias represented lower bias using the CKD-EPI equation compared with the MDRD equation. Data on difference in bias between equations and mean bias for each equation were pooled using random-effects inverse-variance weighted meta-analysis. If the SD could not be calculated from standard error or confidence intervals (CI), it was imputed by taking the mean SD from studies in which it could be calculated. We examined the impact of imputed SDs by conducting additional analyses which excluded studies where SDs could not be calculated.

Difference in mean accuracy was calculated by taking the differences in accuracy between eGFR by subtracting MDRD accuracy from CKD-EPI accuracy. A negative accuracy therefore represented higher accuracy using the MDRD equation compared with the CKD-EPI equation. Data on difference in mean accuracy between equations and mean accuracy for each equation were pooled using random-effects inverse-variance weighted meta-analysis. Standard errors of the accuracy were calculated as square root of $[\text{proportion} \times (1 - \text{proportion}) / n]$. Studies were ordered in forest plots by mean mGFR in the included patients (low to high). Subgroup analyses were used to compare low and high mGFR ($< 60 \text{ ml/min/1.73m}^2$, $\geq 60 \text{ ml/min/1.73m}^2$ respectively) for the difference in bias and difference in accuracy between MDRD and CKD-EPI.

Heterogeneity is reported using the I^2 statistic (15). High heterogeneity was investigated using random-effects meta-regression of each outcome separately against three pre-specified key parameters that differed between renal clinic populations and primary care populations: mGFR, age and gender.

We assessed potential publication bias through sensitivity analyses excluding smaller studies (<100 participants).

Analyses were carried out using Stata (StataCorp. Stata Statistical Software: Release 14.1. College Station, TX) using the commands metan (16) and metareg (16).

RESULTS

Fig. 1 summarises the process of identification and selection of studies. In total, 9559 references were identified after duplicates were removed and 8030 were excluded after title and abstract review. Of the 1529 full-text articles that were reviewed, 182 studies reported eGFR but were excluded because they had no extractable data, did not use both MDRD and CKD-EPI equations, or did not use isotope dilution-mass spectrometry traceable assays. These and other reasons for exclusion are shown in Fig. 1 (1481 excluded studies). Forty-eight studies of 26,875 patients met all the inclusion criteria.

Characteristics of the included studies are summarised in Table 1. Of the 48 included studies, some studies separately reported data from multiple subgroups, resulting in 60 comparisons. Twenty-nine studies (31 comparisons) reported both mean bias and P_{30} , one study reported mean bias only and 18 studies (29

comparisons) reported P_{30} only. The mean age of participants across studies was 57 y, 52% were male, and mean $\pm$ SD mGFR was 71.5 $\pm$ 23.5 ml/min/1.73m².

The methodological quality was assessed in all included studies; only three studies were considered as unclear in five or more of the areas for consideration. For the domains of 'index test' and 'reference standard' no studies were assessed as high risk of bias, two studies were assessed as high risk of bias for 'flow and timing' and for all three domains the majority of studies (>85%) were assessed as low risk and therefore high quality. The domain of 'patient selection' was variable and in almost half of the papers it was not possible to determine the degree of bias due to inadequate descriptions of recruitment processes (online Supplemental Table 1).

Difference in bias between CKD-EPI and MDRD equations for eGFR

Across the 30 studies of 7453 patients that reported mean bias, the difference in bias was 2.2 ml/min/1.73m² (95% CI 1.1 to 3.2) lower in eGFR estimated using CKD-EPI than using MDRD (Fig. 2), but there was high heterogeneity between studies ($I^2=74.4\%$, $p<0.0001$). Sub-group analysis of low and high mGFR showed CKD-EPI had significantly lower bias than MDRD only for those studies with mean mGFR ≥ 60 ml/min/1.73m² (Fig. 2). Considering bias in the MDRD equation, eGFR on average, across all studies, was 4.7 ml/min/1.73m² (95% CI 0.8 to 8.7) lower than mGFR, but varied between studies with high heterogeneity ($I^2=99.2\%$, $p<0.0001$). Bias in the CKD-EPI equation was on average lower than mGFR by 2.8 ml/min/1.73m² (95% CI 0.5 to 6.0) with variation between studies ($I^2=99.0$, $p<0.0001$) (Fig. 3). Similar results were obtained in sensitivity analyses excluding one study ([17](#)) in which standard deviation was estimated or excluding studies with fewer than 100 participants (data not shown).

Difference in accuracy between CKD-EPI and MDRD equations for eGFR

Accuracy estimates for both formulae were reported in 47 studies of 26,358 patients. In a meta-analysis, mean accuracy of CKD-EPI was 2.7% higher than MDRD (95% CI 1.6 to 3.8) with moderate heterogeneity across studies ($I^2=55.5\%$, $p<0.0001$) (Fig. 4). Sub group analysis of low and high mGFR showed CKD-EPI had significantly higher accuracy than MDRD only for those studies with mean mGFR ≥ 60 ml/min/1.73m². Mean accuracy of MDRD equation was 74% (95% CI 71 to 77) with high heterogeneity ($I^2=97.8\%$, $p<0.0001$) whereas mean accuracy of the CKD-EPI equation was 77% (95% CI 74 to 80) again with high heterogeneity ($I^2=98.6\%$, $p<0.0001$) (Fig. 5). Similar results were obtained in sensitivity analyses excluding studies with fewer than 100 participants (data not shown).

Relationship of bias and accuracy to renal function in each study

In meta-regression analyses, difference in bias between equations increased with increasing mGFR. Thus for each 10 ml/min/1.73m² increase in mGFR the difference in bias increased by 0.8 ml/min/1.73m² (0.3 to 1.3; $p=0.002$). Difference in accuracy between equations increased in favour of CKD-EPI with increasing mGFR. For each 10 ml/min/1.73m² increase in study mean mGFR, the difference in accuracy (P_{30}) increased by an additional 0.9% (0.4 to 1.5; $p=0.001$) (Supplemental Fig. 1).

No association was found between mean bias of the MDRD equation and increasing mean mGFR using meta-regression ($p=0.325$). MDRD mean accuracy increased with mean mGFR. For each 10 ml/min/1.73m² increase in study mean mGFR, the accuracy (P_{30}) of eGFR increased by an additional 2.5% (1.1 to 3.9; $p=0.001$) (Data not shown). Neither bias nor accuracy were associated with mean patient age ($p=0.975$, $p=0.382$ respectively) or the proportion of men ($p=0.63$, $p=0.894$

respectively), and we found no factor that reduced the I^2 statistics for heterogeneity by more than 5%.

No association was found between mean bias of the CKD-EPI equation and increasing mean mGFR using meta-regression ($p=0.594$). CKD-EPI mean accuracy increased with mean mGFR. For each 10 ml/min/1.73m² increase in study mean mGFR, the accuracy (P_{30}) of eGFR increased by an additional 3.6% (2.4 to 4.9; $p<0.0001$) (Data not shown). Neither bias nor accuracy were associated with patient age ($p=0.476$, $p=0.291$ respectively) or the proportion of men in the study ($p=0.983$, $p=0.744$ respectively), and no factor reduced the I^2 statistics for heterogeneity by more than 5%.

DISCUSSION

In populations relevant to primary care, we found that both the MDRD and CKD-EPI equations underestimated GFR, but that estimates from CKD-EPI were slightly more accurate than those from MDRD. Clinical and statistical heterogeneity between studies was high. In studies with lower mean levels of renal function (mGFR < 60 ml/min/1.73m²) eGFR was no different whether using CKD-EPI or MDRD. However, at higher levels of renal function CKD-EPI performed better than MDRD both in terms of bias and accuracy. Therefore, given the distribution of renal function seen in primary care patients ([11](#)), this study supports the recent decision in national guidelines to estimate GFR using the CKD-EPI equation ([4](#)).

Our analysis shows that absolute bias is smaller in CKD-EPI than MDRD; however, it varies in both direction and magnitude between studies (high statistical heterogeneity for both mean absolute bias and mean bias).

Bias alone is not a straightforward indicator of accurate estimation of GFR, because high variability can cause poor accuracy even when bias is low. Therefore, our analyses of accuracy (P_{30}) are potentially more indicative of overall usefulness of the two equations. On this metric too, CKD-EPI performs better than MDRD, but the mean effect is small compared to the variation between studies.

Both the MDRD and CKD-EPI equations estimate GFR using the same variables (age, gender, ethnicity and serum creatinine), but there were large differences in the distribution of renal function in the populations from which they were derived. The MDRD study population had CKD and a mean GFR of 40 mL/min/1.73m²,[\(6\)](#) while the CKD-EPI study population included subjects with and without CKD who had a mean GFR of 68 mL/min/1.73m² [\(7\)](#). Differences in non-renal determinants of serum creatinine, such as muscle mass and diet, are likely to contribute to the differences in equation performance seen across the range of renal function [\(18\)](#), as may the analytical techniques used to measure serum creatinine. Our results are consistent with a smaller systematic review [\(18\)](#). A further study reported that while CKD-EPI has slightly better performance, assessed using bias and accuracy, the differences were not clinically significant, other than bias at very low levels of renal function [\(19\)](#).

Further improvement in estimating renal function is, however, needed. Guidelines suggest that the proportion of eGFR measurements within 30% of mGFR should exceed 90% [\(20\)](#), yet accuracy within studies was rarely this high. Given that creatinine measurements have high levels of laboratory and biological variability [\(5, 21\)](#), alternative filtration markers, such as cystatin C, that are less dependent on muscle mass, may give better estimates of GFR, and have been included in UK guidelines for a more secure early stage diagnosis of CKD [\(4\)](#). While measured

GFR is sometimes used in clinical practice when a high degree of precision is required ([22](#), [23](#)), it is not a practical solution at population level in primary care.

This is the most comprehensive systematic review and meta-analysis to examine the accuracy of MDRD and CKD-EPI, by comparing eGFR with mGFR, in populations where relevance to primary care has been assessed. While the majority of studies did not clearly recruit from community settings, we used mean study mGFR to construct meta-regressions that estimate bias and accuracy at the higher levels of renal function seen in primary care populations. We used broad inclusion criteria, including all studies that compared eGFRs derived from MDRD or CKD-EPI with mGFR. A smaller previous review only presented descriptive results and restricted inclusion to larger studies comparing eGFRs derived from two or more equations with mGFR ([18](#)). While this means we have included smaller studies, sensitivity analyses excluding those with fewer than 100 participants, to investigate publication bias, gave similar results. Furthermore, effects were tested at the study level rather than individual level.

The quality of patient selection in included studies was variable; in many studies the generalisability of individual studies was unclear due to recruitment methods. Different reference tests for mGFR were used and the effect of this on equation performance is not known. The high clinical and statistical heterogeneity requires caution in the interpretation of specific numerical results, such as the estimates of mean bias and mean accuracy for each equation. However, there is a direct link between meta-analysis size and detected heterogeneity ([24](#)) and the within-study analysis of difference in accuracy supports the interpretation that CKD-EPI can be more accurate than MDRD. Additionally, some large studies reported metrics that were not analysable, such as median bias or mean % difference, and could therefore

not be included in the meta-analysis. If these studies reported a smaller bias or accuracy, then our meta-analyses could be overestimating the effect sizes.

In summary, CKD-EPI gave more accurate estimates of mGFR particularly in populations with higher mGFR (better renal function), such as those seen in primary care. However, continued investigation of improved estimating equations, novel biomarkers, or both, are merited to optimise CKD detection and monitoring.

Acknowledgements

We would like to acknowledge the reviewers for their comments on the manuscript.

Contributors: DL, JH and CO'C conceived and designed the study. DL, EM and RS planned the statistical analysis. JH did the literature search. DL, JH, JV, JM, EM, CO'C did the study selection and data extraction. DL, CO'C and FDRH clinically interpreted data. EM and DL wrote the first draft of the manuscript. All authors had full access to the data, and contributed to the final version of the manuscript. DL had final responsibility for the decision to submit for publication.

Funding: This paper presents independent research funded by the National Institute for Health Research (NIHR) under the Programme Grants for Applied Research programme (RP-PG-1210-12003) and School for Primary Care Research (SPCR 156). This study represents the views of the authors and not necessarily those of the NIHR, the NHS or the Department of Health. The funders of the study had no role in study design, data collection, analysis, interpretation, or writing of the report. DL was supported by the NIHR Oxford Biomedical Research Centre and NIHR Oxford Diagnostic Evidence Cooperative. FDRH is partly supported by NIHR School for

264 Primary Care Research, NIHR CLAHRC Oxford, NIHR Oxford BRC and Harris
265 Manchester College.
266

References

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;351:1296-305.
2. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet* 2012;380:807-14.
3. Jha V, Garcia-Garcia G Fau - Iseki K, Iseki K Fau - Li Z, Li Z Fau - Naicker S, Naicker S Fau - Plattner B, Plattner B Fau - Saran R, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013;382:260-72.
4. National Institute for Health and Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. CG182. London: Department of Health; 2014.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int* 2013;3 Suppl:1-150.
6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461-70.
7. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro lii AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604-12.
8. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012;367:20-9.
9. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. *N Engl J Med* 2013;369:932-43.
10. Botev R, Mallie JP, Wetzels JF, Couchoud C, Schuck O. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. *Clin J Am Soc Nephrol* 2011;6:937-50.

11. O'Callaghan CA, Shine B, Lasserson DS. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. *BMJ Open* 2011;1:e000308.
12. NHS Employers. Changes to QOF 2015/2016 2014.
<http://www.nhsemployers.org/your-workforce/primary-care-contacts/general-medical-services/quality-and-outcomes-framework/changes-to-qof-2015-16> (accessed April 2017)
13. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m². *Am J Kidney Dis* 2010;56:486-95.
14. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-36.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
16. Harbord RM HJ. Meta-regression in Stata. *Stata Journal* 2008;8(4):493-519.
17. Lemoine S, Guebre-Egziabher F, Dubourg L, Hadj-Aissa A. Are GFR estimating formulas inaccurate in obese patients? [abstract] *Nephrol Dial Transplant* 2013;28:i126.
18. Earley A MD, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. *Ann Intern Med* 2012;156:785-95.
19. Delanaye P PH, Botev R, Inker LA, Levey AS. Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation? *Nephrol Dial Transplant* 2013;28:1396-403.
20. K/DOQI Clinical Practice Guidelines on Chronic Kidney Disease: Work Group and Evidence Review Team Membership. *Am J Kidney Dis* 2002;39 Suppl:S1-S266.
21. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011;80:17-28.
22. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. *J Am Soc Nephrol* 2009;20:2305-13.

23. Delanaye P, Mariat C. The applicability of eGFR equations to different populations. *Nat Rev Nephrol* 2013;9:513-22.
24. Kontopantelis E, Springate DA, Reeves D. A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. *PLoS One* 2013;8:e69930.
25. Altiparmak MR, Seyahi N, Trabulus S, Yalin SF, Bolayirli M, Andican ZG, et al. Applicability of a different estimation equation of glomerular filtration rate in Turkey. *Ren Fail* 2013;35:1116-23.
26. Arreola-Guerra JM, Rincon-Pedrero R, Cruz-Rivera C, Belmont-Perez T, Correa-Rotter R, Nino-Cruz JA. Performance of MDRD-IDMS and CKD-EPI equations in Mexican individuals with normal renal function. *Nefrologia* 2014;34:591-8.
27. Bevc S, Hojs R, Ekart R, Gorenjak M, Puklavec L. Simple cystatin C formula compared to serum creatinine-based formulas for estimation of glomerular filtration rate in patients with mildly to moderately impaired kidney function. *Kidney Blood Press Res* 2012;35:649-54.
28. Bevc S, Hojs R, Ekart R, Zavrsnik M, Gorenjak M, Puklavec L. Simple cystatin C formula for estimation of glomerular filtration rate in overweight patients with diabetes mellitus type 2 and chronic kidney disease. *Exp Diabetes Res* 2012;2012:179849.
29. Bhuvanakrishna T, Blake GM, Hilton R, Burnapp L, Sibley-Allen C, Goldsmith D. Comparison of estimated GFR and measured GFR in prospective living kidney donors. *Int Urol Nephrol* 2015;47:201-8.
30. Bjork J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmo Study cohort. *Scand J Clin Lab Invest* 2011;71:232-9.
31. Bjork J, Jones I, Nyman U, Sjostrom P. Validation of the Lund-Malmo, Chronic Kidney Disease Epidemiology (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) equations to estimate glomerular filtration rate in a large Swedish clinical population. *Scand J Urol Nephrol* 2012;46:212-22.
32. Bouqueneau A, Vidal-Petiot E, Vrtovsni F, Cavalier E, Rorive M, Krzesinski JM, et al. Modification of diet in renal disease versus chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in obese patients. *Nephrol Dial Transplant* 2013;28 Suppl:iv122-iv30.
33. Camargo EG, Soares AA, Detanico AB, Weinert LS, Veronese FV, Gomes EC, et al. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation

366 is less accurate in patients with Type 2 diabetes when compared with healthy
 367 individuals. *Diabet Med* 2011;28:90-5.

368 34. Chen LI, Guh JY, Wu KD, Chen YM, Kuo MC, Hwang SJ, et al. Modification of
 369 Diet in Renal Disease (MDRD) study and CKD Epidemiology Collaboration (CKD-
 370 EPI) equations for Taiwanese adults. *PLoS ONE* 2014;9:e99645.

371 35. Chung BH, Yu JH, Cho HJ, Kim JI, Moon IS, Park CW, et al. Comparison of
 372 Estimating Equations for the Prediction of Glomerular Filtration Rate in Kidney
 373 Donors before and after Kidney Donation. *PLoS ONE* 2013;8:e60720.

374 36. Craig AJ, Britten A, Heenan SD, Irwin AG. Significant differences when using
 375 MDRD for GFR estimation compared to radionuclide measured clearance. *Eur*
 376 *Radiol* 2011;21:2211-7.

377 37. Craig AJ, Britten A, Heenan SD, Irwin AG. Should the MDRD, CKD-EPI and
 378 Cockcroft-Gault equations be used for a Nuclear Medicine population[abstract].? *Eur*
 379 *J Nucl Med Mol Imaging* 2011;Suppl:S407.

380 38. Cvan Trobec K, Kerec Kos M, von Haehling S, Anker SD, Macdougall IC,
 381 Ponikowski P, et al. Iohexol clearance is superior to creatinine-based renal function
 382 estimating equations in detecting short-term renal function decline in chronic heart
 383 failure. *Croat Med J* 2015;56:531-41.

384 39. Du X, Hu B, Jiang L, Wan X, Fan L, Wang F, et al. Implication of CKD-EPI
 385 equation to estimate glomerular filtration rate in Chinese patients with chronic kidney
 386 disease. *Ren Fail* 2011;33:859-65.

387 40. Eriksen Bjorn O, Mathisen Ulla D, Melsom T, Ingebretsen Ole C, Jenssen Trond
 388 G, Njolstad I, et al. Cystatin C is not a better estimator of GFR than plasma
 389 creatinine in the general population. *Kidney Int* 2010;78:1305-11.

390 41. Flamant M, Haymann JP, Letavernier E, Vidal-Petiot E, Boffa JJ, Vrtovsni F.
 391 Estimation of GFR in the elderly: Which formula should be used [abstract]? *Nephrol*
 392 *Dial Transplant* 2012;27:ii97.

393 42. Hu SL, Igari M, Walle NL, Steffes MW, Beland MD, Collins SA, et al. Kidney
 394 transplant donor glomerular filtration rate by iohexol clearance during computerized
 395 tomographic angiography of the kidneys. *Transplant Proc* 2013;45:3229-33.

396 43. Iliadis F, Ntemka A, Didangelos T, Makedou A, Margaritidis C, Moravidis E, et al.
 397 Estimation of glomerular filtration rate in type 2 diabetic patients using the new CKD-
 398 EPI equation [abstract]. *Diabetes Technol Ther* 2011;13:218.

399 44. Jeong TD, Lee W, Chun S, Lee SK, Ryu JS, Min WK, et al. Comparison of the
400 MDRD study and CKD-EPI equations for the estimation of the glomerular filtration
401 rate in the Korean general population: The fifth Korea National Health and Nutrition
402 Examination Survey (KNHANES V-1). 2010. *Kidney Blood Press Res* 2013;37:443-
403 50.

404 45. Jessani S, Levey AS, Bux R, Inker LA, Islam M, Chaturvedi N, et al. Estimation
405 of GFR in South Asians: A study from the general population in Pakistan. *Am J*
406 *Kidney Dis* 2014;63:49-58.

407 46. Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, et al.
408 Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI
409 (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly.
410 *Am J Kidney Dis* 2013;61:57-66.

411 47. Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y, et al. Evaluation of the Chronic Kidney
412 Disease Epidemiology Collaboration equation for estimating glomerular filtration rate
413 in the Chinese population. *Nephrol Dial Transplant* 2013;28:641-51.

414 48. Koppe L, Klich A, Dubourg L, Ecochard R, Hadj-Aissa A. Performance of
415 creatinine-based equations compared in older patients. *J Nephrol* 2013;26:716-23.

416 49. Krones E, Fickert P, Zitta S, Neunherz S, Artinger K, Reibnegger G, et al. The
417 chronic kidney disease epidemiology collaboration equation combining creatinine
418 and cystatin C accurately assesses renal function in patients with cirrhosis. *BMC*
419 *Nephrol* 2015;16:196

420 50. Liu X, Chen J, Wang C, Shi C, Cheng C, Tang H, et al. Assessment of
421 glomerular filtration rate in elderly patients with chronic kidney disease. *Int Urol*
422 *Nephrol* 2013;45:1475-82.

423 51. Liu X, Qiu X, Shi C, Huang H, Huang J, Li M, et al. Modified glomerular filtration
424 rate-estimating equations developed in Asiatic population for Chinese patients with
425 type 2 diabetes. *Int J Endocrinol* 2014;2014:521071.

426 52. Liu X, Gan X, Chen J, Lv L, Li M, Lou T. A new modified CKD-EPI equation for
427 Chinese patients with type 2 diabetes. *PLoS ONE*. 2014;9:e109743.

428 53. Lopes MB, Araujo LQ, Passos MT, Nishida SK, Kirsztajn GM, Cendoroglo MS, et
429 al. Estimation of glomerular filtration rate from serum creatinine and cystatin C in
430 octogenarians and nonagenarians. *BMC Nephrol* 2013;14:265

431 54. Lujan PR, Chiurchiu C, Douthat W, de Arteaga J, de la Fuente J, Capra RH, et
432 al. CKD-EPI instead of MDRD for candidates to kidney donation. *Transplantation*
433 2012;94:637-41.

434 55. MacIsaac RJ, Ekinci EI, Premaratne E, Lu ZX, Seah JM, Li Y, et al. The Chronic
435 Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve
436 the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and
437 preserved renal function. *BMC Nephrol* 2015;16:198.

438 56. Maple-Brown LJ, Ekinci EI, Hughes JT, Chatfield M, Lawton PD, Jones GR, et al.
439 Performance of formulas for estimating glomerular filtration rate in Indigenous
440 Australians with and without type 2 diabetes: the eGFR Study. *Diabet Med*
441 2014;31(7):829-38.

442 57. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT.
443 Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation
444 to GFR, age, and body size. *Clin J Am Soc Nephrol* 2010;5:1003-9.

445 58. Murata K, Baumann A, Saenger AK, Larson TS, Rule AD, Lieske JC. Relative
446 performance of the MDRD and CKD-EPI equations for estimating glomerular
447 filtration rate among patients with varied clinical presentations. *Clin J Am Soc*
448 *Nephrol* 2011;6:1963-72.

449 59. Nyman U, Grubb A, Sterner G, Bjork J. The CKD-EPI and MDRD equations to
450 estimate GFR. Validation in the Swedish Lund-Malmö Study cohort. *Scand J Clin*
451 *Lab Invest* 2011;71:129-38.

452 60. Nyman U, Grubb A, Larsson A, Hansson LO, Flodin M, Nordin G, et al. The
453 revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI
454 across GFR, age and BMI intervals in a large Swedish population. *Clin Chem Lab*
455 *Med* 2014;52:815-24.

456 61. Obiols J, Bargnoux A-S, Kuster N, Fesler P, Pieroni L, Badiou S, et al. Validation
457 of a new standardized cystatin C turbidimetric assay: evaluation of the three novel
458 CKD-EPI equations in hypertensive patients. *Clin Biochem* 2013;46:1542-7.

459 62. Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin
460 P, Susantitaphong P, et al. The need for robust validation for MDRD-based
461 glomerular filtration rate estimation in various CKD populations. *Nephrol Dial*
462 *Transplant* 2011;26:2780-5.

63. Qiu L, Guo X, Zhu Y, Shou W, Gong M, Zhang L, et al. Effect of picric acid and enzymatic creatinine on the efficiency of the glomerular filtration rate predictor formula. *Clin Lab* 2013;59:511-22.
64. Sagou Yayo E, Aye M, Konan JL, Emieme A, Attoungbre ML, Gnionsahe A, et al. Inadequacy of the African-American ethnic factor to estimate glomerular filtration rate in an African general population: Results from Cote d'Ivoire. *Nephrol Ther* 2016;12:454-9.
65. Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. *Ann Intern Med* 2012;157:471-81.
66. Silveiro SP, Araujo GN, Ferreira MN, Souza FDS, Yamaguchi HM, Camargo EG. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation pronouncedly underestimates glomerular filtration rate in type 2 diabetes. *Diabet Care* 2011;34:2353-5.
67. Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, et al. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. *Am J Kidney Dis* 2013;62:531-40.
68. Tent H, Rook M, Stevens LA, van Son WJ, van Pelt LJ, Hofker HS, et al. Renal function equations before and after living kidney donation: a within-individual comparison of performance at different levels of renal function. *Clin J Am Soc Nephrol* 2010;5:1960-8.
69. Teo BW, Xu H, Shuter B, Wang D, Li J, Sinha AK, et al. Assessment of the CKD-EPI and MDRD equations in a multi-ethnic Asian chronic kidney disease population[abstract]. *Nephrology* 2010;15 Suppl3:40.
70. Valente MA, Hillege HL, Navis G, Voors AA, Dunselman PH, van Veldhuisen DJ, et al. The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. *Eur J Heart Fail* 2014;16:86-94.
71. Veronese FV, Gomes EC, Chanan J, Carraro MA, Camargo EG, Soares AA, et al. Performance of CKD-EPI equation to estimate glomerular filtration rate as compared to MDRD equation in South Brazilian individuals in each stage of renal function. *Clin Chem Lab Med* 2014;52:1747-54.

497

498 **Table 1. Characteristics of studies using both MDRD and CKD-EPI and IDMS-**499 **traceable assays**

Author	Year	N	Recruitment setting	Population	mGFR	Age, y	% Male	Reported
Altiparmak (25)	2013	229	Renal	mix	45.6	53.9	49	Mean bias P30
Arreola-Guerra (26)	2014	97	NR	healthy	102.7	35.8	58.8	Mean bias P30
Bevc (27)	2012A	255	Renal	mix	55.5	59.7	53.7	Mean bias P30
Bevc (28)	2012	113	Renal	mix	42.9	64	61.9	Mean bias P30
Bhuvanakrishna (29)	2015	508	Potential donor	healthy	91.7	44.1	48	P30
Bjork (30)	2011	850	Other	mix	55	60	55.8	P30
Bjork (31)	2012	996	Other	healthy	44	61	56.1	P30
Bouqueneau (32)	2013	366	Other	mix	56	55	49.5	Mean bias P30
Camargo (33)	2011	55	Other	healthy	98	58	49	Mean bias P30
Camargo (33)	2011	56	Other	diabetes	106	58	49	Mean bias P30
Chen (34)	2014	139	Hospital	mix	68.8	51	51	P30
Chung (35)	2013	207	Potential donor	healthy	116.3	40.4	42	Mean bias P30
Craig (36 , 37)	2011	516	Other	mix	65	61	54	Mean bias
Cvan (38)	2015	43	Other	CHF	53.1	73	58	Mean bias P30
Du (39)	2011	142	Other	renal	41.77	65.2	59.9	Mean bias P30
Eriksen (40)	2010	1621	Primary Care	healthy	91.7	56.9	49.3	P30
Flamant (41)	2012	782	Other	renal	42.6	72.8	65.2	P30
Hu (42)	2013	17	Potential donor	healthy		47	75	Mean bias P30
Iliadis (43)	2011	448	Diabetes	diabetes	72	65	47	Mean bias P30
Jeong (44)	2013	607	Other	mix	NR	NR	NR	Mean bias P30
Jessani (45)	2014	581	Primary Care	mix	91	50.6	50.3	P30
Kilbride (46)	2013	394	Primary Care	mix	NR	80	48	P30
Kong (47)	2013	977	Renal	mix	68.3	48.3	49	Mean bias P30
Koppe (48)	2013	224	Renal	mix	41.3	75.3	57.1	P30
Krones (49)	2015	24	Potential donor	healthy	97.5	51	25	Mean bias P30
Lemoine (17)	2013	218	Other	mix	51.8		57.8	P30
Levey (7)	2009	3896	Renal	healthy	68	50	55	P30
Liu (50)	2013	332	Renal	renal	39.7	70	62	Mean bias P30
Lui (51)	2014A	209	Hospital	diabetes	47.9	61.6	57.4	Mean bias P30
Lui (52)	2014	351	Hospital	non-diabetes	60.7	58.3	59.5	P30
Lui (52)	2014	351	Hospital	diabetes	62.8	60.3	59.3	P30

Lui (52)	2014	210	Hospital	diabetes				P30
Lopes (53)	2013	95	Other	healthy	55	85.3	30	Mean bias P30
Lujan (54)	2012	85	Potential donor	healthy	116	41	45.9	Mean bias P30
MacIsaac (55)	2015	199	Diabetes	diabetes	80	62.8	67	Mean bias P30
Maple-Brown (56)	2014	224	Other	diabetes	97	52	37	P30
Maple-Brown (56)	2014	340	Other	non-diabetes	108	40	39	P30
Michels (57)	2010	271	Primary Care	mix	72.6	44.3	44	Mean bias P30
Murata (58)	2011	583	Other	healthy	98.9	56.1	55	P30
Murata (58)	2011	2324	Other	renal	98.9	56.1	55	P30
Nyman (59)	2011	850	Other	healthy	55	60	56	P30
Nyman (60)	2014							P30
Obiols (61)	2013	100	Other	mix	90	53.6	55	Mean bias P30
Praditpornsilpa (62)	2011	350	Other	renal	55.86	59.5	44.9	Mean bias P30
Qiu (63)	2013	176	Other	renal	40.7	48.8	51.6	Mean bias P30
Sagou (64)	2016	120	Other	healthy	100	34	50	Mean bias P30
Schaeffner (65)	2012	570	Primary Care	mix	60.4	78.5	57.2	Mean bias P30
Silveiro (66)	2011	105	Diabetes	diabetes	103	57	50	Mean bias P30
Spithoven (67)	2013	336	Renal	healthy	97.7	53.1	48	Mean bias P30
Tent (68)	2010	253	Potential donor	healthy	103	49.5	43	P30
Teo (69)	2010	232	Renal	renal	51.7	58.4	52	P30
Valente (70)	2014	120	Hospital	CHF	74	59	80	Mean bias P30
Veronese (71)	2014	354	Other	mix	87	53	45	Mean bias P30

NR: Not reported

Figure1. Study flow chart.

Figure 2. Difference in mean bias from CKD-EPI and mean bias from MDRD, and pooled estimate (diamond) stratified into subgroups of high and low mGFR using random effects meta-analysis

Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis

Figure 3. Mean bias between eGFR and mGFR calculated using MDRD (left) and CKD-EPI (right) equations, stratified into subgroups of high and low mGFR using random effects meta-analysis

Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis

Figure 4. Difference in mean accuracy from CKD-EPI and mean accuracy from MDRD, and pooled estimate (diamond) stratified into subgroups of high and low mGFR using random effects meta-analysis. (P_{30} – proportion of eGFR results within 30% of mGFR result)


Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis

527 Figure 5. Mean accuracy between eGFR and mGFR calculated using MDRD (left)
528 and CKD-EPI (right) equations, stratified into subgroups of high and low mGFR using
529 random effects meta-analysis

530 *Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis*


531

532 Figure 1




533


534 Figure 2



535



537



539

